ARIA Risk, APOE4 and Alzheimer’s Treatment Explained
When I was diagnosed with Alzheimer’s and learned that APOE could affect my risk of ARIA, I realized I didn't understand the difference between a gene, an allele, and a protein. This is the story of what I learned; what ARIA is; how to understand an APOE genetic blood test, what the risks are and how the risk is monitored.
Leqembi and p-tau217: A Blood Test Offers a New Window Into Alzheimer’s
A personal look at what happened to my p-tau217 blood levels after starting Leqembi, and how new research suggests that changes in this Alzheimer’s biomarker may provide an early indication of how patients are responding to treatment.
p-tau217 Blood Test: What Your Result Means
What does your p-tau217 blood test actually mean? Learn what p-tau217 measures, how it relates to beta-amyloid, why laboratory cutoffs differ, and why the number is not a measure of Alzheimer’s severity.
Tau PET Scans in Alzheimer’s
Tau PET is becoming an important new window into Alzheimer’s disease. With the August 2026 FDA approval of Tauklarify, clinicians now have two FDA-approved tau PET tracers—Tauvid and Tauklarify. Unlike amyloid testing, which helps identify whether Alzheimer’s biology is present, tau PET can show where aggregated tau has accumulated and how extensively it has spread. This high-level guide explains what tau PET adds, how the two tracers differ, and why tau imaging may become increasingly important for understanding disease stage and progression.